Health Canada approves ADTRALZA® (tralokinumab) for the treatment of adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis

TORONTO, Feb. 8, 2023 – LEO Pharma Inc. today announced the Health Canada approval of Adtralza® (tralokinumab) for adolescent…